Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-deve...
Main Authors: | Charles A. Kunos, Jacek Capala |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/13/10/287 |
Similar Items
-
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
by: Charles A. Kunos, et al.
Published: (2019-03-01) -
Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer
by: Charles A. Kunos, et al.
Published: (2020-08-01) -
Radiopharmaceuticals for Relapsed or Refractory Leukemias
by: Charles A. Kunos, et al.
Published: (2019-02-01) -
A Theoretical View of Ovarian Cancer Relapse
by: Gonzalo H. Giornelli, et al.
Published: (2017-08-01) -
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)